Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1010-1018

  Piesche, Matthias ^a   Ho, Vincent T ^a   Kim, Haesook ^b   Nakazaki, Yukoh ^a   Nehil, Michael ^a   Yaghi, Nasser K ^a   Kolodin, Dmitriy ^c   Weiser, Jeremy ^a   Altevogt, Peter ^d   Kiefel, Helena ^d   Alyea, Edwin P ^a   Antin, Joseph H ^a   Cutler, Corey ^a   Koreth, John ^a   Canning, Christine ^a   Ritz, Jerome ^a   Soiffer, Robert J ^a   Dranoff, Glenn ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIC PROTEIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTIBODY; CYTOKINE; DEVELOPMENTAL ENDOTHELIAL LOCUS 1 PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; NERVE CELL ADHESION MOLECULE L1; PLATELET DERIVED GROWTH FACTOR; PROGRANULIN; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; ANTIBODY RESPONSE; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMORAL IMMUNITY; LEUKEMIA REMISSION; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; ADVERSE EFFECTS; ALLOTRANSPLANTATION; GENE LIBRARY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA; LONGITUDINAL STUDY; METABOLISM; MORTALITY; OUTCOME ASSESSMENT; REPRODUCIBILITY; TIME FACTOR;

ANGIOGENESIS INDUCING AGENTS; ANTIBODIES; CANCER VACCINES; CYTOKINES; GENE LIBRARY; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LONGITUDINAL STUDIES; PATIENT OUTCOME ASSESSMENT; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84929485506     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1956     Document Type: Article

References (50)

1. Copelan EA Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-26.
2. Ofran Y, Ritz J. Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation. Clin Cancer Res 2008; 14: 4997-9.
3. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol 2006; 90: 133-73.
4. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973-8.
5. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-9.
6. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005; 11: 1230-7.
7. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117: 2197-204.
8. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907-12.
9. Alpdogan O, Eng JM, Muriglan SJ, Willis LM, Hubbard VM, Tjoe KH, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005; 105: 865-73.
10. Mirmonsef P, Tan G, Zhou G, Morino T, Noonan K, Borrello I, et al. Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood 2008; 111: 2112-21.
11. Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001; 61: 162-71.
12. Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 2009; 106: 15825-30.
13. Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv Immunol 2006; 90: 337-60.
14. Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, et al. ATP6S1 elicits potent humoralresponses associated with immune mediated tumor destruction. Proc Natl Acad Sci U S A 2002; 99: 6919-24.
15. Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun 2003; 3: 3-20.
16. Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003; 100: 3398-403.
17. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 2006; 103: 9190-5.
18. Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, et al. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res 2008; 14: 3896-905.
19. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, et al. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 2010; 70: 10150-60.
20. Nagao H, Setoguchi T, Kitamoto S, Ishidou Y, Nagano S, Yokouchi M, et al. RBPJ is a novel target for rhabdomyosarcoma therapy. PLoS ONE 2012; 7: e39268.
21. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012; 4. pii: a008052.
22. Takayama K, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T, et al. TACC2 is an androgen-responsive cell-cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol Endocrinol 2012; 26: 748-61.
23. Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 2012; 11: 923-36.
24. Raveh S, Gavert N, Ben-Ze'ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett 2009; 282: 137-45.
25. Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, et al. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol 2009; 41: 1572-80.
26. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006; 66: 936-43.
27. Hanayama R, Tanaka M, Miwa K, Nagata S. Expression of developmental endothelial locus-1 in a subset ofmacrophages for engulfment of apoptotic cells. J Immunol 2004; 172: 3876-82.
28. Aoka Y, Johnson FL, Penta K, Hirata Ki K, Hidai C, Schatzman R, et al. The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. Microvascular Res 2002; 64: 148-61.
29. Martin V, Liu D, Fueyo J, Gomez-Manzano C. Tie2: ajourney from normal angiogenesis to cancer and beyond. Histol Histopathol 2008; 23: 773-80.
30. Schoenfeld JD, Dranoff G. Anti-angiogenesis immunotherapy. Human Vaccines 2011; 7: 976-81.
31. Toh H, Cao M, Daniels E, Bateman A. Expression of the growth factor progranulin in endothelial cells influences growth and development of blood vessels: a novel mouse model. PLoS ONE 2013; 8:e64989.
32. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011; 55: 261-8.
33. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 2012; 18: 1118-22.
34. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-95.
35. Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res 2013; 1: 11-5.
36. Fonseca C, Soiffer R, Ho V, Vanneman M, Jinushi M, Ritz J, et al. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood 2009; 113: 1681-8.
37. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
38. Reikvam H, Hatfield KJ, Fredly H, Nepstad I, Mosevoll KA, Bruserud O. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw 2012; 23: 140-53.
39. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis inthe bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-44.
40. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-13.
41. Shih TT, Hou HA, Liu CY, Chen BB, Tang JL, Chen HY, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009; 113: 3161-7.
42. Trujillo A, McGee C, Cogle CR. Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012; 2012: 128608.
43. Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud O. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opin Investig Drugs 2010; 19: 169-83.
44. Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577-85.
45. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-93.
46. Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010; 116: 1539-47.
47. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive Strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
48. Wu C, Yang X-F, McLaughlin S, Neuberg D, Canning C, Stein B, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106: 705-14.
49. Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP, et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656-63.
50. Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, BhuiYanS, Cutler CS, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versushost disease. Blood 2011; 117: 2275-83.